Jinzhou Jiutai Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise with a production history of more than 60 years. The predecessor of Jinzhou No. 1 pharmaceutical factory was founded in 1951 and restructured into Jinzhou Jiutai Pharmaceutical Co., Ltd. in 1998. In recent years, various economic indicators have been among the top 100 pharmaceutical production enterprises in China. It is one of the key pharmaceutical enterprises in Liaoning Province. It has successively won the honorary titles of provincial advanced enterprise, provincial civilized unit, provincial science and technology leading enterprise and provincial user satisfaction enterprise. "Jiutai" trademark is also recognized as "China famous" trademark by the State Administration for Industry and commerce. The company covers an area of 58000 square meters, has a registered capital of 40.46 million yuan and has 1250 employees, including 310 engineering and technical personnel; It has 5 production workshops, 1 R & D center and 1 holding pharmaceutical commercial company. The company produces nearly 100 varieties. Chlorhexidine API is the earliest manufacturer in China. Suppository products with chlorhexidine as raw materials have formed a series of products covering the whole country; Solid preparation products have formed two series of antipyretic analgesics and digestive system drugs; Powder injection "pantoprazole sodium for injection" is a national class IV new drug with remarkable effect in the treatment of peptic ulcer. The company's gynecological medication has always been at the leading level in China. It is the only "gynecological medication production base" designated by the former State Administration of medicine. The company has reasonable product structure and good economic operation. Advanced production technology, mature process route, complete quality monitoring system and stable and reliable product quality.Jiutai Pharmaceutical Co., Ltd. is a provincial enterprise technology R & D center. Over the years, our company has successfully developed raw materials such as chlorhexidine, malotilate, omeprazole sodium, pantoprazole sodium, betahistine hydrochloride, ethylenediamine diacetyl aminoacetate, polyhexamethylene biguanide hydrochloride (pHMB), as well as more than ten preparation varieties such as Sanwei Hemorrhoids Suppository, chlorhexidine suppository, metronidazole furazolidone suppository (Jiutai Kunbao), azithromycin fumarate capsule, etc, There are six new drugs to fill the gap in China. It has formed four series of products represented by chlorhexidine raw materials, gynecological suppositories, anti peptic ulcer drugs and antipyretic analgesics. The national first-class new drug "tranbuterol hydrochloride" developed by the company in cooperation with Shenyang Pharmaceutical University and with completely independent intellectual property rights was included in the national Torch Plan in 2008, included in the major scientific and technological special project of "major new drug creation" of the Ministry of science and technology in 2009, and obtained seven patents in seven countries. These patents will effectively protect the long-term market of "tranbuterol hydrochloride".